5 August 2021
Absence of stem cells in pancreas changes view on pancreatic cancer
New research by Oncode Investigator Louis Vermeulen and co-investigator Maarten Bijlsma shows that there are no stem cells in the pancreas. These unexpected findings potentially have major implications for pancreatic cancer research, since stem cells are often at the root of tumor development. This research was published today in the leading journal Cell Stem Cell.
27 July 2021
Antibodies with a mission: what the Utrecht Monoclonal Antibody Facility (UMab) can do for you
As part of the Infrastructure and Technology programme, Oncode started a collaborative project together with Oncode Investigator Linde Meyaard (UMCU) and Jeanette Leusen (head of the Utrecht Monoclonal Antibody Facility (UMab)) with the goal of being able to offer Oncode Investigators the opportunity to produce high quality antibodies (targeted against membrane proteins). Oncode is now looking to fund a total of 4 Oncode Investigators to develop monoclonal antibodies potentially suited for clinical applications in oncology, directed against their membrane target of choice.
20 July 2021
Oncode collaboration results in a new mathematical method that can predict cancer survival based on genetic changes
As cancer survival rates vary widely, Oncode Researcher Daniel Miedema from Oncode Investigator Louis Vermeulen’s lab (Amsterdam UMC), in collaboration with the teams of Oncode Investigators Hugo Snippert (UMC Utrecht) and Geert Kops (Hubrecht Institute) has developed a mathematical method to predict survival based on genetic changes in cancer. The results of this study are now published in Nature Communications.
14 July 2021
Oncode Investigators Hugo Snippert and Jarno Drost receive NWO-Vidi grant
Just announced: The Dutch Research Council has awarded Oncode Investigators Hugo Snippert (UMCU) and Jarno Drost (Princess Máxima Center for pediatric oncology) a NWO-Vidi grant worth 800.000 Euros. The Vidi grant is part of the NWO Talent Programme and will enable them to develop their own innovative line of research in the coming five years.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more